Navigation Links
Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
Date:5/21/2008

rate gluten proteins and have an inflammatory response to the gluten in wheat, barley and rye. This results in varying symptoms such as fatigue, skin rash, anemia, fertility issues, joint pain, weight loss, pale sores inside the mouth, tooth discoloration or loss of enamel, depression, chronic diarrhea or constipation, gas and abdominal pain. The immunology and nutritional abnormalities in celiac disease can potentially result in long-term complications such as osteoporosis, refractory sprue, small intestinal cancer, and lymphoma. The only current treatment for CD is complete elimination of gluten from the diet, which results in remission for most patients, but can be very difficult to implement in practice. "However, the response to the gluten-free diet is poor in up to 30% of patients and dietary nonadherence is the chief cause of persistent or recurrent symptoms."(3)

About "Larazotide Acetate"

Larazotide acetate is an experimental medicine and an inhibitor of barrier dysfunction that has been shown to block abnormally increased intestinal permeability and the genesis of some autoimmune diseases, either as a result of reduction of antigen presentation to the body's immune system, or through inhibitory, direct effects on gastrointestinal associated lymphoid tissue. Larazotide acetate is a non-absorbed peptide which improves mucosal barrier function by inhibiting cytoskeletal reorganization and tight junction disassembly. Larazotide acetate is orally formulated, has been granted "Fast Track" designation by the U.S. Food and Drug Administration for the treatment of celiac disease, and is also being evaluated for the treatment of Crohn's Disease. Results of the Company's first study in celiac patients are available online at: http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2036.2007.03413.x

About Alba

Alba Therapeutics Corporation i
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
2. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
3. PacificGMP Completes GMP Product Fill for Trius Therapeutics
4. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
5. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
6. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
7. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
8. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
9. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
10. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
11. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... SHENZHEN , Chine, 3 juillet 2015 ... séquençage à haut débit de l,ADN situé à ... la certification de  l,American College of Pathologists  (Collège ... BGI à Hong Kong ... nouvelle génération à recevoir la certification du CAP ...
(Date:7/2/2015)... and VANCOUVER , July 2, 2015 ... EPI) announced today that its common shares have been approved ... under the symbol "EPIX". ESSA will begin trading ... its listing on the TSX Venture Exchange under the symbol ... the common shares on the NASDAQ, each of the Company,s ...
(Date:7/2/2015)... July 2, 2015  New product launches are critical ... role in educating thought leaders about new products, Medical ... influence how well a new therapy performs at launch. ... research and consulting leader Best Practices, LLC, critical aspects ... focus on are early stage thought leader (TL) interaction, ...
Breaking Medicine Technology:BGI obtient la certification du Collège des pathologistes américains (CAP) 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 4Medical Affairs Role in Thought Leader Education is Key Success Factor for New Product Launches in the Pharmaceutical Industry 2
... DALLAS, April 4, 2008 Data from five ... presented at the National Kidney,Foundation (NKF) 2008 Spring ... utilization studies involve PROCRIT(R) (Epoetin alfa)., The ... and,costs of PROCRIT (EPO) and darbepoetin alfa (DARB), ...
... Previously-Stated Guidance Remains Unchanged, PRINCETON, N.J., ... MEDX ) today issued the following statement ... that it was discontinuing its Phase 3 ... anti-CTLA-4,antibody (tremelimumab) compared to chemotherapy in patients ...
Cached Medicine Technology:Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 2Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 3Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 4Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 5Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 6Medarex Announces Ipilimumab Program Continues to Move Forward 2Medarex Announces Ipilimumab Program Continues to Move Forward 3Medarex Announces Ipilimumab Program Continues to Move Forward 4Medarex Announces Ipilimumab Program Continues to Move Forward 5
(Date:7/3/2015)... ... July 03, 2015 , ... Smoothies are all the rage right now and ... accessible, quality ingredients. Aurora Natural is proud to introduce a new line of all ... protein, antioxidants, vitamins and minerals! , Aurora is offering a variety of blends and ...
(Date:7/3/2015)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in ... biblical truth and expose popular lies regarding proper relationships according to the bible. ... goes into the core of the subject by explaining why certain types of sexual ...
(Date:7/2/2015)... ... 2015 , ... sweetFrog Enterprises, LLC. is pleased to announce the opening of ... located in the Lone Star State. The premium frozen yogurt chain was listed as ... store, which opened July 1 at Duke’s Travel Plaza, is located at:, 30176 Hwy ...
(Date:7/2/2015)... ... July 02, 2015 , ... With summer in full swing, Americans are flocking to ... of the top spots for fishing in the world, and it’s easy to understand why. ... Canada has great fish. , Recreational fishing is a huge industry, and Americans make ...
(Date:7/2/2015)... ... , ... Global leader and compression innovator, SIGVARIS North America, is ... For style that’s quick on its feet, men will love this fun new way ... everywhere because a simple change in socks can dramatically help improve overall leg health ...
Breaking Medicine News(10 mins):Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2Health News:sweetFrog Expands Texas Footprint with Location in Canton 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 3
... Standard" Preventive Medical Exams; New Women,s ... MCKINNEY, Texas, Oct. 18 Signaling the next ... wellness-focused residential,community under development in McKinney, the Cooper ... public. "Father of aerobics" Dr. Kenneth Cooper, who,founded ...
... HR 971 Would Increase the Cost of Prescription ... Care,Management Association (PCMA) issued the following statement in ... hearing on,legislation that would grant independent pharmacists sweeping ... a worse time for policymakers and,consumers alike. As ...
... per cent of psychiatric nurses believe that people with Borderline ... one in fifty adults suffer from the condition, according to ... Health Nursing. , Ninety-eight per cent of nurses said service ... cent said that disagreements between staff on how to care ...
... children under 6, and they may do harm, critics say ... panel of experts at the U.S. Food and Drug Administration ... medicines for young children. , Such a ban already has ... a 365-page review on the issue in late September. Any ...
... in ... women,s health, SAN ... National Association of Nurse,Practitioners in Women,s Health (NPWH) Women,s Health Research ... to the authors of four abstracts to recognize their,outstanding contributions to ...
... announced the,launch of a small group product designed ... UPMC Health Plan,s Small Business Advantage. UPMC,Health Plan ... 99,employees a high- quality, easy-to-implement program of competitive,benefits, ... account manager and customer service team. UPMC ...
Cached Medicine News:Health News:Cooper Clinic at Craig Ranch Opens Signaling the Next Phase of CooperLife Health-Focused Residential Community in McKinney 2Health News:Cooper Clinic at Craig Ranch Opens Signaling the Next Phase of CooperLife Health-Focused Residential Community in McKinney 3Health News:Services for patients with BPD need to be improved say psychiatric nurses 2Health News:Services for patients with BPD need to be improved say psychiatric nurses 3Health News:FDA Panel Weighs Ban on Kids' Cold Medicines 2Health News:FDA Panel Weighs Ban on Kids' Cold Medicines 3Health News:FDA Panel Weighs Ban on Kids' Cold Medicines 4Health News:Mission Pharmacal Congratulates Exemplary Women's Health Researchers 2Health News:Mission Pharmacal Congratulates Exemplary Women's Health Researchers 3Health News:Mission Pharmacal Congratulates Exemplary Women's Health Researchers 4Health News:Mission Pharmacal Congratulates Exemplary Women's Health Researchers 5Health News:Mission Pharmacal Congratulates Exemplary Women's Health Researchers 6Health News:Mission Pharmacal Congratulates Exemplary Women's Health Researchers 7Health News:UPMC Health Plan Launches New Product for Small Businesses 2
All oral and nasal airways are manufactured with smooth, rounded edges for increased patient comfort and safety., ,Portex® offers a broad selection of airways for a variety of clinical applicati...
... latex. Available in even sizes 20-36F. ... maximizing patient comfort., ,The Latex-Free ... maximize patient comfort while offering the ... is economically priced allowing you to ...
Soft red rubber. Adjustable flange. Pediatric sizes available....
Soft Non-Latex, Adjustable Flange Nasopharyngeal Airway. Pediatric sizes available. Non-Latex Mediprene material with soft elastic finish. Adjustable flange for a better fit and increased patient com...
Medicine Products: